Disc Medicine Highlights Advancements at EHA Congress 2025
WATERTOWN, Mass. – Disc Medicine, Inc. (NASDAQ:IRON), a pioneering biopharmaceutical firm focused on innovative hematology treatments, is set to present vital data from its diverse pipeline at the upcoming European Hematology Association (EHA) 2025 Congress. This notable event will unfold in Milan, showcasing significant developments across Disc’s hematology programs.
Multiple Presentations Showcase Pipeline Progress
During this year's EHA Congress, Disc Medicine will unveil findings from several programs, highlighting important advancements in their clinical trials. These presentations will include data from the HELIOS long-term extension trial of bitopertin, along with findings from the Phase 1b study of DISC-0974 for anemia associated with myelofibrosis. The company will also provide results from the studies involving DISC-3405 conducted in healthy volunteers.
Leadership Insights on Future Directions
John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc Medicine, shared his enthusiasm regarding the upcoming presentations. "As we move forward toward key company milestones, we are dedicated to showcasing the steady progress within our pipeline,” he noted. This statement underscores the organization's commitment to delivering innovative solutions to hematologic diseases.
Key Presentation Highlights
Disc Medicine will host a corporate update call to further discuss the exciting data presented at the Congress. This call is scheduled for June 16 at 8:00 am ET, aiming to engage with stakeholders and relay essential updates regarding the research findings.
Here are the details of the highlighted presentations at the conference:
Bitopertin Presentation
Abstract Number: PS2210
Title: Results from the HELIOS Study: A Phase 2, Open-Label, Long-Term Extension Study of Bitopertin in Erythropoietic Protoporphyria
Date / Time: June 14, 6:30 pm CEST / 12:30 pm ET
Presenting Author: Melanie Chin
DISC-0974 Presentations
Abstract Number: PF856
Title: A Phase 1b/2 Study of DISC-0974, An Anti-Hemojuvelin Antibody, In Patients with Myelofibrosis and Anemia
Date / Time: June 13, 6:30 pm CEST / 12:30 pm ET
Presenting Author: Sima Bhatt
Abstract Number: PS1845
Title: DISC-0974 (An Anti-Hemojuvelin Antibody) in Non-Transfusion-Dependent Patients with Myelofibrosis: Laboratory Correlates of Major Anemia Response
Date / Time: June 14, 6:30 pm CEST / 12:30 pm ET
Presenting Author: Ayalew Tefferi
Abstract Number: PS1814
Title: Anti-Hemojuvelin Monoclonal Antibody Further Enhances Hematologic Response to ESA and/or Luspatercept in Mice
Date / Time: June 14, 6:30 pm CEST / 12:30 pm ET
Presenting Author: Min Wu
DISC-3405 Presentations
Abstract Number: PF1216
Title: An Iron Pulse Study to Assess Oral Iron Absorption Following Treatment with DISC-3405 in Healthy Volunteers
Date / Time: June 13, 6:30 pm CEST / 12:30 pm ET
Presenting Author: Guowen Liu
Abstract Number: PS2207
Title: Single- and Multiple- Ascending Doses of DISC-3405, A Recombinant Humanized Antibody Targeting TMPRSS6, Increased Hepcidin and Reduced Iron and Hematocrit in Healthy Volunteers
Date / Time: June 14, 6:30 pm CEST / 12:30 pm ET
Presenting Author: Marcus Carden
About Disc Medicine
Disc Medicine is on the cutting edge of biopharmaceutical solutions, dedicated to providing novel treatments for patients with serious hematological diseases. The company is actively developing a rich portfolio focused on addressing unmet medical needs through innovative mechanisms, particularly aimed at enhancing the treatment landscape and improving patients' quality of life.
Frequently Asked Questions
What key data will Disc Medicine present at the EHA Congress?
Disc Medicine will showcase data from the HELIOS long-term extension trial of bitopertin and further findings from the studies of DISC-0974 and DISC-3405.
When is the corporate update call scheduled?
The corporate update call is scheduled for June 16 at 8:00 am ET.
Who will present the HELIOS study findings?
Melanie Chin will present the findings from the HELIOS study at the Congress.
What is the focus of the upcoming presentations?
The focus will be on the efficacy and safety of treatments for serious hematologic conditions, particularly regarding anemia in myelofibrosis and protoporphyria.
How can one stay updated on Disc Medicine’s progress?
Individuals can visit Disc Medicine’s website for updates on their clinical studies and corporate events.
